| Migraine Disorders
Aimovig vs Ajovy
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Aimovig vs Ajovy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAjovy has a higher rate of injection site reactions vs Aimovig based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ajovy but not Aimovig, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aimovig
Ajovy
At A Glance
SC injection
Once monthly
CGRP receptor antagonist
SC injection
Monthly or every 3 months
CGRP antagonist
Indications
- Migraine Disorders
- Migraine Disorders
- Episodic migraine
Dosing
Migraine Disorders 70 mg SC once monthly; some patients may benefit from 140 mg SC once monthly.
Migraine Disorders 225 mg SC monthly or 675 mg SC quarterly (three consecutive 225 mg injections) into abdomen, thigh, or upper arm.
Episodic migraine Pediatric patients 6 to 17 years weighing 45 kg or more: 225 mg SC monthly.
Contraindications
- Serious hypersensitivity to erenumab-aooe or any excipient (reactions have included anaphylaxis and angioedema)
- Serious hypersensitivity to fremanezumab-vfrm or any excipient, including anaphylaxis and angioedema
Adverse Reactions
Most common (>=3%) Injection site reactions, constipation
Serious Hypersensitivity reactions, constipation with serious complications, hypertension, Raynaud's phenomenon
Postmarketing Hypersensitivity reactions (rash, angioedema, anaphylaxis), constipation with serious complications, oral mucosal ulceration, rash, alopecia, hypertension, Raynaud's phenomenon
Most common (>=2%) Injection site reactions (pain, induration, erythema)
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Anaphylactic reactions, angioedema, hypertension, Raynaud's phenomenon
Pharmacology
CGRP receptor antagonist; human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.
Fremanezumab-vfrm is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, thereby inhibiting CGRP-mediated signaling implicated in migraine.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aimovig
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (1/12)
Ajovy
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (7/12) · Qty limit (10/12)
UnitedHealthcare
Aimovig
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (1/8)
Ajovy
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Aimovig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Ajovy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/momo
Aimovig CoPay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AimovigView full Aimovig profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.